US Patent

US10517882 — Method for healing of an infected acne lesion without scarring

Method of Use · Assigned to Foamix Pharmaceuticals Ltd · Expires 2030-10-01 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating or alleviating skin disorders, including acne, using a topical hydrophobic gel or foam composition containing a tetracycline antibiotic.

USPTO Abstract

Methods of treatment and dosage regimes using hydrophobic gel or foam compositions comprising a tetracycline antibiotic for accelorating the return of skin integrity and or in treating or alleviating a disorder including impetigo, acne, rosacea, a skin disease caused by a bacteria or a tetracycline antibiotic responsive disease, wherein the foam composition or gel is administered topically to a target area on a subject having the disorder and wherein the target area comprises an area of skin, or mucosa or an eye.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2647 minocycline-hydrochloride

Patent Metadata

Patent number
US10517882
Jurisdiction
US
Classification
Method of Use
Expires
2030-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Foamix Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.